Depression and stress levels increase risk of liver cancer through epigenetic downregulation of hypocretin

Chunyun Pu a,1, Shaorong Tian a,1, Sanxiu He a, Weihong Chen a, Yuanyuan He b, Hongyan Ren c, Jing Zhu d, Jun Tang a, Xiaolan Huang e, Ying Xiang a, Yixiao Fu f, Tingxiu Xiang a,*

a Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China
b Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China
c Department of Urinary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China
d Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China
e Ph.D Research Center for Medical and Social Development, Chongqing Medical University, Chongqing 400016, PR China
f Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China

Received 25 August 2020; accepted 24 November 2020
Available online 2 December 2020

Abstract Recent studies suggest that Hypocretin (HCRT, Orexin) are involved in stress regulation of depression through the hypothalamic-pituitary-adrenal (HPA) axis. However, the molecular mechanism by which Hypocretin regulate neurobiological responses is unknown. Herein, the effects of chronic stress on the epigenetic modification of HCRT and its association with depression were explored with regard to a potential role in cancer progression. In the study, Sprague Dawley (SD) rats were used to establish an animal model of cancer with depression by administrating n-nitrosodiethylamine (DEN) and chronic unpredictable mild stress (CUMS). RNA-sequencing was used to detect differentially expressed genes in the hippocampus of rats and quantitative real-time polymerase chain reaction (qRT-PCR) was used to validate the results of RNA-sequencing. The status of HCRT promoter methylation was assessed by methylation specific polymerase chain reaction. Behavioral tests showed that rats exposed...
Introduction

Major depressive disorder (MDD) is a serious mental disorder, prevalently among cancer patients. Among cancer patients, the morbidity of depression is approximately 12.5%, which is four times that of the general population. Epidemiological studies have found that depression have a lot of negative influence on cancer populations, including shortened survival, fatigue, reduced treatment compliance, reduced quality of life, and increased risk for suicide. Depression has been associated with poor prognosis and increased cancer mortality. A meta-analysis of 160,000 patients found that self-report psychological stress is epidemiologically associated with multiple cancer deaths. However, cancer is a highly heterogeneous disease, cancer occurrence and development affected by a variety of factors, and the relationship between depression and cancer is still remain controversial. In recent years, advances in the neurobiology of depression and the physiopathology of cancer have identified common bio-behavioral mechanisms suggested associations between depression and cancer progression. Chronic stress-mediated inflammatory dysbiosis and immunosuppression increased susceptibility for many chronic diseases, including depression and cancer. Stress appears to contributed to different stages of tumor progression, including tumorigenesis, angiogenesis and diffusion metastasis. At the molecular level, epigenetic regulation influences gene expression in susceptible individuals, and which may be associated with the interactions among environmental stress exposure, endocrine modulation and immune dysfunction.

Hypocretin (HCRT, also known as Orexin) is an excitatory neuropeptide secreted by neurons on the lateral side of the hypothalamus and around the fornix, which acts via two G protein-coupled receptors, hypocretin-receptor-1 and -2. HCRT and its receptors are found in many brain regions including the prefrontal cortex (PFC), hippocampus, almond nucleus and ventral tegmental area. These regions are closely associated with the hypothalamic-pituitary-adrenal (HPA) axis, which controls the response to stress, and are involved in the homeostasis of digestion, the immune system, emotion, cognition, and energy metabolism. Many preclinical studies have shown that depressive-like behavior in rodents is associated with the function of HCRT. Interestingly, the enhanced or weakened function of HCRT is not only related to the type, intensity, duration, coping style of stress and the response to stressors, but also to different functions of various projected brain regions. However, the cause and the underlying basis for these differences are unclear. DNA methylation is an important epigenetic mechanism that promotes tumorigenesis and tumor progression by silencing tumor suppressor genes. Recent evidences have demonstrated that DNA methylation seems to be associated with depression.

In order to explore the effect of depression on cancer and the molecular basis for their association, we developed a rat model of hepatocellular carcinoma (HCC), also with depression. In this study, we used this rat model to explore the function of HCRT in the hippocampus, firstly revealed that the epigenetic modification of HCRT plays a crucial role in the association between depression and HCC progression.

Materials and methods

Animal study

Thirty-four Sprague Dawley (SD) male (80–100 g, ~3 weeks of age) rats were purchased from Experimental Animal Center of Chongqing Medical University (Chongqing, China). Single-housed rats were kept in animal room at 21 ± 1 °C under, a 12 h dark/light cycle (lights on from 7:00 a.m. to 7:00 p.m.) and 50 ± 5% humidity., Food and water were provided ad libitum. Animal use and procedures were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Ethics Committee of Chongqing Medical University, Chongqing, China. After 1 week of acclimation, the SD rats were weight-matched and randomly divided into three groups: Normal control group (Control, n = 8), Hepato-cellular carcinoma group (HCC, n = 10), and HCC with Depression group (HCC + Dep, n = 16). Rats in the HCC group were administered with a single intraperitoneal injection of n-nitrosodiethylamine (DEN) at a dose of 25 mg/kg of body weight dissolved in 0.9% saline, and started to drink water with 0.01% DEN continuously after 1 week of DEN injection. Besides administered with DEN, Rats in the HCC with Depression group were repeatedly exposed to two or three kinds of chronic unpredictable mild stressors at random each day, which including: food or water...
deprivation, damp bedding (300 mL of water spilled per cage), 45° cage-tilt along the vertical axis, turning night into day, stroboscopic illumination (300 flashes/min) sleep deprivation, behavior restriction, 4 °C ice water swimming and tail nip. The same stimulus was not repeated in two days. Normal control rats were given i.p. injections of saline and normal drinking water without CUMS. After 17 weeks of HCC induction, 5D rats were tested for behaviors. For the pre-experiment section, CUMS last two months was used to induce depression-like behavior in C57 mice. Mice were divided into two groups, depression group and control group, behavioral tests were done according to the methods reported in the literature and tissue samples were collected.

Behavioral tests

Sucrose preference test
In the sucrose preference test (SPT), the rats were been deprived food and water for 12 h before test began. Two transparent water bottles of the same size and shape, one been filled with clean water and the other with 1% sucrose solution, were provided to the same rat concurrently. The test lasted 1 h and bottles with water or solution been weighted before and after the test. The proportion of sucrose consumption in total consumption was calculated.

Open field test
Each rat was placed in the center of an open cube box (100 × 100 × 40 cm) with black opaque bottom and peripheral wall, the movements within 5 min were recorded by a video surveillance (logitech webcam software), and rats allowed 30 s to adapt to the observation box. The total distance travelled for 5 min and the time spent in central zone was assessed. The open-field test (OFT) was carried out in a sound-attenuated room with rats separated to avoid communication between each other. This test been measured one day before modeling and after 17 weeks of CUMS treatment.

Tissue sample collection
Rats were sacrificed the day after the behavioral tests were completed. Hippocampus and liver tissue were immediately dissected, frozen in liquid nitrogen and stored at –80 °C.

DNA and RNA extraction
Genomic DNA was extracted from tissue and cell samples using DNAzol Reagent (Invitrogen) and the QIAamp DNA Mini Kit (Qiagen). Total RNA was isolated from tissue and cell samples using TRIzol (Invitrogen). The concentration of RNA was determined by spectrophotometry using NanoDrop 2000 (Thermo Scientific). DNA and RNA integrity were determined using gel electrophoresis.

Hematoxylin and eosin (HE) staining
Liver tissue was fixed in 10% neutral buffered formalin and embedded in paraffin. After dewaxing and rehydration, HE staining was performed on 5-μm sections following a standard protocol.

Immunohistochemistry
Immunohistochemistry was executed using the UltraSensitive TM SP kit (Maixin-Bio, Fujian, China) according to the instructions. Ki-67 (#9449, Cell Signaling Technology) and Glypican-3 (#MAB-0617, Maixin-Bio, Fujian, China) are diluted at recommended concentrations. The results were determined according to previously published methods.

RNA-sequencing
RNA samples were sent to a Genomics facility (Novogene, Beijing, China) for RNA-Seq. The quality of RNA was assessed using a NanoPhotometer spectrophotometer and a 2100 Bioanalyzer instrument. An RNA library was prepared using the NEB Next Ultra Directional RNA Library Prep Kit for Illumina. Poly-A mRNA was enriched with Oligo (dT) magnetic beads. Libraries were sequenced using an Illumina HiSeq 2000.

Semi-quantitative polymerase chain reaction (PCR) and quantitative real-time PCR (qRT-PCR) analysis
Reverse transcription was performed using Promega GoScript™ reverse transcriptase (Promega). Two μL of cDNA (1200 ng/μL) were added to a 10 μL RT-PCR reaction mixture. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the control. The primer sequences and specific conditions are listed in Table 1. PCR was performed using Go-Taq (Promega). Gel electrophoresis (120 V, 25 min) was performed using 2% agarose gels. Results were obtained using a BioRad Gel Doc XR + system. The qRT-PCR was performed using SYBR Green (Thermo Fisher) following the manufacturer’s instructions (7500 Real-Time PCR System, Applied Biosystems, Foster City, CA, USA). The primers are listed in Table 1. Each sample was tested in triplicate. Gene expression levels were calculated by the 2^−ΔΔCt method.

Methylation-specific PCR (MSP)
Methylation specific polymerase chain reaction (MSP) was conducted for 40 amplification cycles using AmpliTaq™-Gold DNA polymerase (Applied Biosystems), with annealing temperatures of 60 °C and 58 °C for methylated and unmethylated samples, respectively (Table 1). Amplicons were analyzed as previously described.

Clinical research

Subject recruitment
All subjects were recruited from the First Affiliated Hospital of Chongqing Medical University. This study was approved by the Institutional Review Committee and informed consent obtained from all participants. Demographic and clinical characteristics of the participants were collected in the form of a questionnaire including information such as sex, age, body mass index (BMI), tumor type, disease stage, treatment, family history of mental illness, and drug abuse. Individuals who reported current alcohol/substance dependence, lifetime psychotic or bipolar disorder, a family history of MDD, bipolar disorder, or suicide were excluded.
Diagnosis and assessment of depression

Based on the criteria of the American Diagnostic and Statistical Manual of Mental Disorders V (DSM-V), Hamilton depression scale (HAMD-17) was used to evaluate depression in patients with cancer who met the inclusion criteria. The severity of depression was graded by the HAMD score.

Whole blood sample determination

After giving written informed consent, venous blood collection was performed. Leukocytes were isolated from whole blood. RNA and DNA were extracted for qRT-PCR and MSP, respectively.

Statistical analysis

SPSS 20.0 was used to perform statistical analysis. Difference between two groups was tested by χ². The difference among groups was assessed by one-way ANOVA. Data are expressed as means±SEM. A P-value less than 0.05 was considered statistically significant.

Results

CUMS and HCC animals

CUMS induced depression-like behavior in HCC rats

Weight gain for rats exposed to CUMS was reduced (Fig. 1A). For the SPT, HCC + Dep rats showed obvious depressive-like behavior, and were found to have lower sucrose preference (%) than that of control (P < 0.05). The preference for sucrose was significantly different for HCC vs. HCC + Dep (P < 0.05) (Fig. 1B). For the OFT, the locomotor activity of rats for CUMS was decreased, with obvious anxiety-like behavior. Rats in HCC + Dep traveled a shorter distance than control (P < 0.05), and the total traveling distance for 5 min was significantly increased for HCC vs. HCC + Dep (P < 0.05) (Fig. 1C). The time rats in HCC + Dep spent in central zone was significantly decreased (P < 0.05) (Fig. 1D). OFT, SPT and forced swimming test (FST) was performed in C57 mice, the locomotor activity has no statistical difference, but lower sucrose preference and longer immobility time was been observed in mice with CUMS (Fig. S1A–C).

Effect of CUMS on the tumorigenesis of liver in rats

After 17 weeks of DEN induction, the survival rates of HCC + Dep group and HCC group were 81% (13/16) and 100% (10/10) respectively, the tumor formation rate of HCC + Dep group was 100% (13/13), and that of HCC was 80% (8/10). Rats was scattered, multiple nodules were seen in the liver of rats. Tumor burden of HCC + Dep rats was significantly greater than HCC rats (Fig. 2A). The liver tissue is weighed, nodules larger than 1 mm in diameter on the liver surface were counted and measured. The number and the size of the tumors in HCC rats were significantly lower than those in HCC + Dep rats, the liver/body weight ratios in HCC rats with or without CUMS were both higher than that in control rats (Fig. 2B). The hepatic lobular structure of HCC rats with or without depression was seriously destroyed, and heterotypic cells and cancer cells of different size were seen under microscope (Fig. 2C). Metastatic cancer cells were not be found in lung tissue of HCC rats with or without depression (Fig. 2D).

Compared with the control group, biochemical indicators ALT and AST both were significantly increased in HCC rats with or without depression (Fig. 3A). The

| Table 1 | List of primers used in this study. |
|---------|-----------------------------------|
| Primer  | Sequence (5′→3′)                  | Product size (bp) | PCR cycles | Annealing temperature (°C) |
| PCRT    | rHcrt-F   | TGACGCTGCTGCTGCTGCTA     | 170        | 60         |
|        | rHcrt-R   | TGGACGCTGCTGCTGCTGCTA  |            |            |
|        | HCRT-F    | CGTGACGCTGCTGCTGCTA   |            |            |
|        | HCRT-R    | GTGCAGACGCTGCTGCTA    |            |            |
|        | rKi67F    | CCCCCCATGCATGGAAGAT   |            |            |
|        | rKi67R    | CCCCCCATGCATGGAAGAT   |            |            |
|        | rSurvivinF| TTAAGGAACTGGAAGCTGAG  |            |            |
|        | rSurvivinR| TTAAGGAACTGGAAGCTGAG  |            |            |
|        | rOx1F     | AGGGAATTACCTACCCGCAA  |            |            |
|        | rOx1R     | AGGGAATTACCTACCCGCAA  |            |            |
|        | rOx2F     | CACATGAGAACGTCACCAA   |            |            |
|        | rOx2R     | CACATGAGAACGTCACCAA   |            |            |
|        | rHcrt-m1  | TTGGTCGTCCGCGGTTTGTTC | 135       | 40         | 60         |
|        | rHcrt-m2  | CAAATAAAATACCGCGGAG  |            |            |
|        | rHcrt-m3  | TTGGTCGTCCGCGGTTTGTTC | 139       | 40         | 58         |
|        | HCRT-m1   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m2   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m3   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m4   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m5   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m6   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m7   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m8   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m9   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m10  | CAAATAAAATACCGCGGAG  |            |            |
| MSP     | rHcrt-m1  | TTGGTCGTCCGCGGTTTGTTC | 135       | 40         | 60         |
|        | rHcrt-m2  | CAAATAAAATACCGCGGAG  |            |            |
|        | rHcrt-m3  | TTGGTCGTCCGCGGTTTGTTC | 139       | 40         | 58         |
|        | HCRT-m1   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m2   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m3   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m4   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m5   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m6   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m7   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m8   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m9   | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m10  | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m11  | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m12  | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m13  | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m14  | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m15  | CAAATAAAATACCGCGGAG  |            |            |
|        | HCRT-m16  | CAAATAAAATACCGCGGAG  |            |            |

qRT-PCR: Quantitative reverse transcription-PCR; MSP: Methylation-specific PCR.
expression of Ki67 or Survivin, tumorigenesis related biological markers, was increased in HCC vs. control, and also increased in HCC + Dep vs. HCC (Fig. 3B). Tumorigenesis at the protein level was further validated by immunohistochemistry (IHC) staining. Stronger nuclear staining of Ki67 and stronger plasma staining of Glypican 3 were observed in HCC + Dep than that in HCC (Fig. 3C, D).

RNA-sequencing
Differentially expressed genes (DEG) within the hippocampus of HCC Rats with or without depression was assessed. A total of 339 DEGs were identified in HCC + Dep vs. HCC, including 182 upregulated and 157 downregulated genes (Fig. 4A). Of the 16,099 genes assessed, 14,357 were identified in HCC and in the HCC + Dep groups (Fig. 4B). The clustering of DEGs in different samples showed that Hcrt was downregulated in HCC + Dep vs. HCC (Fig. 4C). DEGs within the hippocampus of C57 mice with or without depression was been observed, 1210 upregulated and 922 downregulated genes was obtained separately of total 23,524 identified DEGs (Fig. S1D). The 21 enriched pathways revealed by KEGG analysis in Depression vs. Control are shown as a Bubble Diagram, this analysis revealed enriched pathways to be mainly concentrated in neuroactive ligand–receptor interaction, calcium signaling pathway, axon guidance, and ras signaling pathway (Fig. S1E).

RNA-Seq was used for three pairwise comparisons of DEGs in liver tissue of rats, Control vs. HCC, Control vs. HCC + Dep, and HCC vs. HCC + Dep. Volcano plots (Fig. 5A) showed the distribution of DEGs for each comparison. The heat map (Fig. 5B) provided a visual representation of expression levels for all DEGs of the three groups. The Venn diagram (Fig. 5C) describes the total number of DEGs in each pairwise comparison and shows the number of shared DEGs between different comparisons. The results showed that HCRT was significantly down regulated both in rat’s hippocampus and liver in the HCC with Depression group compared to the other two groups.

Epigenetic Hcrt downregulation is associated with emotional regulation in rats
To validate RNA-Seq results, the hippocampal expression of Hcrt in HCC and HCC + Dep was assessed. Compared to HCC, Hcrt expression was significantly lower in the hippocampus of HCC + Dep rats (Fig. 6A). Results were further
Figure 2  Positive effect of CUMS on the tumor burden of the liver in rats. (A) Representative images with front and back side of liver from three groups rats (Normal control, HCC and HCC + Dep rats). (B) Results of tumors counts on the liver surface, max tumor size and the rate of liver weight/body weight. Results are shown as the mean ± SEM, *P < 0.05. (C, D) Representative H&E staining of liver and lung sections in three groups of rats. Scale bars 50 μm.
validated by analysis of Hcrt expression in the livers of three groups of rats (Fig. 6B, F). Hcrt mRNA expression was significantly reduced in HCC vs. Control, and further reduced in HCC + Dep vs. Control. The mRNA expression of orexin receptor 1 (Ox1r) and orexin receptor 2 (Ox2r) in the hippocampus of HCC rats were detected, the expression of Ox1r mRNA has no significant difference in the comparison of HCC + Dep vs. HCC, but Ox2r mRNA expression was significantly reduced in HCC + Dep vs. HCC (Fig. 6C). Subsequently, Ox2r mRNA expression was detected to be down-regulated in HCC and further down-regulated in HCC + Dep compared with control group (Fig. 6D). HCRT mRNA

Figure 3  Positive effect of CUMS on the tumorigenesis and progression of the liver in rats. (A) Results of liver function in three groups of rats. ALT, Alanine transaminase; AST, aspartate aminotransferase. Data represent mean ± SEM, *P < 0.05. (B) The expression of Ki67 mRNA and Survivin mRNA were detected by qRT-PCR (**P < 0.01, ***P < 0.001). (C, D) Validation of tumour tumorigenesis at the protein levels by IHC staining. Scale bars 100 μm.
Expression in whole blood tissues of human was detected, the result indicated that HCRT down-regulated in patients with depression compared with normal (Fig. 6E). These results are consistent with RNA-Seq data, suggesting a crucial role for Hcrt in rat emotional regulation.

To investigate whether promoter hyper-methylation was responsible for decreased Hcrt expression in CUMS rats, DNA samples from rat hippocampus were assessed by MSP. Higher promoter methylation levels were related to lower Hcrt expression in the hippocampus of CUMS rats (Fig. 6F).

Clinical study of depression in cancer
A total of 123 clinical cancer patients were considered for this study based on the DSM-V diagnostic criteria. Patients were excluded who had primary neurological or psychiatric disorders. Patients were considered to have depression with an HAMD scale score $\geq 17$. The demographic characteristics of clinical cases were shown in Table 2. Results showed that there were no significant difference based on age, gender, marital status, stage of tumor, course of disease, type of therapeutic regimen or BMI in comparison of...
cancer patients with or without depression ($P > 0.05$).
Among cancer types, lung cancer, colorectal cancer, breast cancer and nasopharyngeal carcinoma accounted for a higher proportion than others. No statistical difference was found in the comparison of cancer types between the two groups ($P > 0.05$).

Promoter methylation downregulates HCRT in patients with depression
To confirm whether promoter hypermethylation was responsible for decreased HCRT expression in depression, blood leucocyte DNA from clinical patients was assessed by MSP. The HCRT promoter was methylated in 25 of 41 (61%) cancer patients with depression and methylated in 7 of 23 (30%) of cancer patients without depression. Moreover, the HCRT promoter was essentially unmethylated in 16 normal control blood samples, and methylated in 3 of 7 (43%) blood samples from individuals with simple depression (Table 3). In summary, greater promoter methylation levels were associated with lower HCRT expression and depression ($P < 0.05$) (Fig. 7D).

**Discussion**

In this study, we provide evidence that supports HCRT as an emotional regulatory factor that influences the affective behavioral phenotype, depression. The stress-induced depressive phenotype promoted tumorigenesis and progression of HCC. HCRT expression was downregulated in depression and HCC, which has been shown to be associated with HCRT promoter methylation. Further, epigenetic HCRT downregulation was more significantly in HCC with depression, and higher promoter methylation levels was related to lower HCRT expression in those with depression. These results suggested epigenetic HCRT promoter methylation may be a molecular mechanism by which depression is associated with cancer.

Previous studies have found Hcrt to be associated with depressive-like behaviors in rodents.27–30 This is consistent with the results of this study in that rats exposed to CUMS for an extended period had significant anxiety and
depression-like behaviors, with reduced Hcrt mRNA expression in the depressed rats. Interestingly, Hcrt function differs in different brain regions, with the function of Hcrt especially unclear in the hippocampus. In this study RNA-Seq revealed Hcrt mRNA expression was found to be lower in the hippocampus of depressed mice or rats. Particularly, lower Oxr2 mRNA expression was found in the hippocampus and liver of HCC rats with CUMS than that in HCC rats without CUMS. Our results reveal a crucial role of Hcrt in the regulation of depressive behavioral phenotypes, and a recent research evidence provided a reliable support that Orx2 agonist can effectively reduce anxiety and depressive behavior in susceptible mice.

It is well-known that the relationship between depression and cancer initiation and/or progression is very complex. Existing data are inconclusive. Depression has been shown to have negative effects in various cancer populations and to increase the risk for cancer. However, other studies showed that depression did not increase the risk for cancer. In the latest preclinical study, social failure rats with long-term anxiety and depression had more lung tumors and higher tumor load. Surprisingly, a similar result was found herein, with the number of liver tumors and tumor burden in rats with CUMS significantly higher than that in rats without CUMS. Expression of Ki67 and Survivin, tumorigenesis related biological markers, were found higher in HCC + Dep group than that in HCC group, suggesting more cell proliferation and less apoptosis occurred in HCC rats with depression. The result was further validated at the protein level. These evidences revealed that long-term psychological stressors contribute to tumorigenesis and cancer progression. In addition, we also found Hcrt to be highly expressed in livers of normal rats, but down-regulated in livers of HCC rats, and even lower in HCC + Dep rats. Similar results were found in whole blood samples from clinic patients. These results suggest that reduced Hcrt expression is associated with cancer and depression.

However, the mechanistic basis for the association between cancer and depression remains unclear. Psychological stress-mediated inflammatory dysregulation and immunosuppressive mechanisms are known to increase cancer susceptibility and to influence cancer occurrence, development, and treatment. Yet, evidence at the molecular level is lacking. Recent advances in molecular epigenetics have found that epigenetic mechanisms lead to changes in certain biological processes through their long-term effects on gene expression in susceptible individuals. Promoter hypermethylation within tumors has been demonstrated by many studies, and as well hypermethylation of specific genes has been associated with depression. To explore the molecular basis for the relationship of cancer with depression, we examined the status of Hcrt promoter methylation and found promoter...
methylation to be greater in those with cancer and depression than in those with cancer but without depression. Furthermore, higher promoter methylation levels were correlated with lower HCRT expression. This study demonstrated HCRT promoter hypermethylation to be a potential molecular mechanism by which cancer is associated with depression. However, further investigation is necessary to elucidate the specific role and function of HCRT in the complex relationship of depression with cancer.

Table 2  Demographic characteristics of cancer patients.

| Variables          | N = 123 | Depression | Non-depression | P-value |
|--------------------|---------|------------|----------------|---------|
|                    | n1 = 41 | n2 = 82    |                |         |
| Age/years          | 62.0 ± 12.0 | 64.4 ± 15.1 | 60.7 ± 10.0  | 0.107   |
| ≤60                | 49 (39.8)   | 12 (24.5)   | 37 (75.5)     | 0.090   |
| >60                | 74 (60.2)   | 29 (39.2)   | 45 (60.8)     |         |
| Gender             |          |            |                |         |
| Male               | 61 (49.6) | 18 (29.5)  | 43 (70.5)     | 0.372   |
| Female             | 62 (50.4) | 23 (37.1)  | 39 (62.9)     |         |
| Marital status     |          |            |                |         |
| Married            | 110 (89.4)| 35 (31.8)  | 75 (68.2)     | 0.300   |
| Unmarried          | 13 (10.6)  | 6 (46.2)   | 7 (53.8)      |         |
| Stage of tumor     |          |            |                |         |
| I~II               | 18 (14.6) | 4 (22.2)   | 14 (77.8)     | 0.279   |
| III~IV             | 105 (85.4)| 37 (35.2)  | 68 (64.8)     |         |
| Course of disease/year |      |            |                |         |
| ≤1                 | 80 (65.0) | 22 (27.5)  | 58 (72.5)     | 0.061   |
| >1                 | 43 (35.0) | 19 (44.2)  | 24 (55.8)     |         |
| Type of therapeutic regimen/units |       |            |                |         |
| ≤1                 | 54 (43.9) | 20 (37.0)  | 34 (63.0)     | 0.271   |
| 1~2                | 59 (48.0) | 16 (27.1)  | 43 (72.9)     |         |
| >2                 | 10 (8.1)  | 5 (50.0)   | 5 (50.0)      |         |
| BMI                |          |            |                |         |
| <18.5              | 13 (10.6) | 5 (38.5)   | 8 (61.5)      | 0.914   |
| 18.5~24.99         | 85 (69.1)| 28 (32.9)  | 57 (67.1)     |         |
| >24.99             | 25 (20.3)| 8 (32.0)   | 17 (68.0)     |         |
| Type of cancer     |          |            |                |         |
| LC                 | 32 (26.0)| 10 (31.3)  | 22 (68.8)     | 0.139   |
| CRC                | 20 (16.3)| 8 (40.0)   | 12 (60.0)     |         |
| BRCA               | 9 (7.3)  | 6 (66.7)   | 3 (33.3)      |         |
| NPC                | 21 (17.1)| 4 (19.0)   | 17 (81.0)     |         |
| Others             | 41 (33.3)| 13 (31.7)  | 28 (68.3)     |         |

Note: ▲ Results are presented as Mean ± SD; (N: total participants, n1: participants with depression.) LC, lung cancer; CRC, colorectal cancer; BRCA, breast cancer; NPC, nasopharyngeal carcinoma; Others, cervical cancer, esophageal cancer, tonsil cancer, pancreatic cancer, bladder cancer, prostate cancer, gastric cancer, et al.

Table 3  Methylation status of the HCRT promoter in patients with depression.

| Samples         | HCRT promoter | Frequency of methylation | P-value |
|-----------------|---------------|--------------------------|---------|
|                 | Methylated    | unmethylated              |         |
| Dep (n = 7)     | 3             | 4                        | 43%     | 0.000*** |
| Cancer with Dep (n = 41)| 25    | 16                       | 61%     |         |
| Cancer (n = 23) | 7             | 16                       | 30%     |         |
| NC (n = 16)     | 0             | 16                       | 0%      |         |

Dep, depression; NC, normal control; Samples, blood leucocyte DNA of clinical patients. ***P < 0.001.
Conclusion

This study demonstrated that psychological stress promoted tumorigenesis and cancer progression. Furthermore, downregulation of HCRT in the hippocampus was shown to play a crucial role in emotional regulation, with epigenetic modification of HCRT expression downregulated in cancer and depression. HCRT promoter methylation may be the molecular basis for the association between depression and cancer progression.

Author contributions

TX: conception and design. CP, ST, SH: performed most experiments. JT, TX: performed experiments and analyzed data. CP, YF, YH, HR, JZ: collected samples. TX, CP, ST: drafted the manuscript. XH, YX: reviewed data and the manuscript. TX: reviewed data and finalized the manuscript. All authors reviewed and approved the final version.

Ethics approval and consent to participate

Informed consent was obtained from each participant included in the study. Our experiments were approved by the Institutional Ethics Committees of the First Affiliated Hospital of Chongqing Medical University [approval notice # 20180307], and the study methodologies conformed to the standards set by the Declaration of Helsinki.

Conflict of interests

The authors declare no conflict of interest.

Funding

The study was supported by the National Natural Science Foundation of China (NSFC) (No.#81872380); and the Opening Foundation of Chongqing Key Laboratory of Molecular Oncology and Epigenetics.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.gendis.2020.11.013.

References

1. Lutgendorf SK, Andersen BL. Biobehavioral approaches to cancer progression and survival: mechanisms and interventions. Am Psychol. 2015;70(2):186–197.
2. Faller H, Bülzebruck H, Drings P, Lang H. Coping, distress, and survival among patients with lung cancer. Arch Gen Psychiatry. 1999;56(8):756–762.
3. Cohen L, Cole SW, Sood AK, et al. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS One. 2012; 7(8):e42324.
10. Cattaneo A, Macchi F, Plazzotta G, et al. Inflammation and disease: understanding the protective and damaging effects of stress and stress mediators. *J Pharmacol*. 2008;583(3):174–185.

12. Menke A, Binder EB. Epigenetic alterations in depression and stress mediators. *J Pharmacol*. 2013;170(8):1449–1528.

13. Alexander SP, Benson HE, Faccenda E, et al. The concise guide to PHARMACOLOGY 2013/14: overview. *Br J Pharmacol*. 2013;170(8):1449–1458.

14. Hunt NJ, Rodriguez ML, Waters KA, Machaalani R. Changes in orexin (hypocretin) neuronal expression with normal aging in the human hypothalamus. *Neurobiol Aging*. 2015;36(1):292–300.

15. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell*. 1998;92(4):573–585.

16. Schmitt O, Usunoff KG, Lazarov NE, et al. Orexinergic innervation of the extended amygdala and basal ganglia in the rat. *Brain Struct Funct*. 2012;217(2):233–256.

17. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretin (orexin) project to multiple neuronal systems. *J Neurosci*. 1998;18(23):9996–10015.

18. Wise RA, Rompré PP. Brain reward and dopamine. *Annu Rev Psychol*. 1989;40:191–225.

19. Bonnivier M, Jackson AC, Carter ME, de Lecea L. Antagonistic interplay between hypocretin and leptin in the lateral hypothalamus regulates stress responses. *Nat Commun*. 2015;6:6266.

20. Berridge CW, Espana RA, Vittoz NM. Hypocretin/orexin in arousal and stress. *Brain Res*. 2010;1314:91–102.

21. Johnson PL, Truitt W, Fitz SD, et al. A key role for orexin in panic anxiety. *Nat Med*. 2010;16(1):111–115.

22. Sakurai T. The role of orexin in motivated behaviours. *Nat Rev Neurosci*. 2014;15(11):719–731.

23. Blackwell JE, Alammar HA, Weighall AR, Kellar I, Nash HM. A systematic review of cognitive function and psychosocial well-being in school-age children with narcolepsy. *Sleep Med Rev*. 2017;34:82–93.

24. Lamers F, Vogelzangs N, Merikangas KR, de Jonge P, Penninx BW. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. *Mol Psychiatry*. 2013;18(6):692–699.

25. Sotnikov S, Wittmann A, Bunck M, et al. Blunted HPA axis reactivity reveals glucocorticoid system dysbalance in a mouse model of high anxiety-related behavior. *Cytokine*. 2014;48:41–51.

26. Jalewa J, Wong-Lin K, McGinnity TM, Prasad G, Hörsch C. Increased number of orexin/hypocretin neurons with high and prolonged external stress-induced depression. *Behav Brain Res*. 2014;272:196–204.

27. Chung HS, Kim JK, Kim JW, Kim HM, Yoon BJ. Orexin administration to mice that underwent chronic stress produces bimodal effects on emotion-related behaviors. *Regul Pept*. 2014;194:159–166.

28. Lutter M, Krishnan V, Russo SJ, Jung S, McClung CA, Nestler EJ. Orexin signaling mediates the antidepressant-like effect of calorie restriction. *J Neurosci*. 2008;28(12):3071–3075.

29. Abbas AG, Shoja H, Soya S, Hondo M, Miyakawa T, Sakurai T. Comprehensive behavioral analysis of male Oxtr−/− mice showed impliciation of orexin receptor-1 in mood, anxiety, and social behavior. *Front Behav Neurosci*. 2015;9:324.

30. Grafe LA, Eacret D, Luz S, et al. Orexin 2 receptor regulation of the hypothalamic–pituitary–adrenal (HPA) response to acute and repeated stress. *Neuroscience*. 2017;348:313–323.

31. Grafe LA, Eacret D, Dobkin J, Bhatnagar S. Reduced orexin system function contributes to resilience to repeated social stress. *eNeuro*. 2018;5(2):ENEURO.0273-17.2018.

32. Kim TK, Kim JE, Park JY, et al. Antidepressant effects of exercise are produced via suppression of hypocretin/orexin and melanin-concentrating hormone in the basolateral amygdala. *Neurobiol Dis*. 2015;79:59–69.

33. Esteller M. Cancer epigenomics: DNA methylation and histone-modification maps. *Nat Rev Genet*. 2007;8(4):286–298.

34. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. *Oncogene*. 2002;21(35):5462–5482.

35. Dell’Oso B, D’Addario C, Carlotta Palazzo M, et al. Epigenetic modulation of BDNF gene: differences in DNA methylation between unipolar and bipolar patients. *J Affect Disord*. 2015;2:330–333.

36. Sun H, Kennedy PJ, Nestler EJ. Epigenetics of the depressed brain: role of histone acetylation and methylation. *Neuropharmacology*. 2013;83(1):124–137.

37. Kundakov M, Gudsnuk K, Herbstman JB, Tang D, Perera FP, Champagne FA. DNA methylation of BDNF as a biomarker of early-life adversity. *Proc Natl Acad Sci U S A*. 2015;112(22):6807–6813.

38. Chen N, Nishio N, Ito S, Tanaka Y, Sun Y, Itoe K. Growth arrest and DNA damage-inducible protein (GADD34) enhanced liver inflammation and tumorgenesis in a diethylnitrosamine (DEN)-treated murine model. *Cancer Immunol Immunother*. 2015;64(6):777–789.

39. Zhao WD, Guan S, Zhou KR, et al. In vivo detection of metabolic changes by 1 H-MRS in the DEN-induced hepatocellular carcinoma in wistar rat. *J Cancer Res Clin Oncol*. 2005;131(9):97–102.

40. Zhang N, Li J, Wang H, et al. The level of nesfatin-1 in a mouse gastric cancer model and its role in gastric cancer comorbid with depression. *Shanghai Arch Psychiatry*. 2015;30(2):119–126.

41. Yuan S, Jiang X, Zhou X, Zhang Y, Teng X, Xie P. Insosine alleviates depression-like behavior and increases the activity of the ERK-CREB signaling in adolescent male rats. *Neuroreport*. 2018;29(14):1223–1229.

42. Cal L, Li R, Tang WJ, Meng G, Hu XY, Wu TN. Antidepressant-like effect of geniposide on chronic unpredictable mild stress-induced depressive rats by regulating the hypothalamic–pituitary–adrenal axis. *Eur Neuropsychopharmacol*. 2015;25(8):1332–1341.
44. Li Y, Huang J, Zeng B, et al. PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation. *Cancer Lett*. 2018;430:109–122.

45. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods*. 2001;25(4):402–408.

46. Yin X, Xiang T, Li L, et al. DACT1, an antagonist to Wnt/beta-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer. *Breast Cancer Res*. 2013;15(2):R23.

47. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry*. 1960;23:56–62.

48. Staton CD, Yaeger JDW, Khalid D, et al. Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression. *Neuropsychopharmacology*. 2018;143:79–94.

49. Irie M, Miyata M, Kasai H. Depression and possible cancer risk due to oxidative DNA damage. *J Psychiatr Res*. 2005;39(6):553–560.

50. Dalton SO, Mellemkjaer L, Olsen JH, Mortensen PB, Johansen C. Depression and cancer risk: a register-based study of patients hospitalized with affective disorders, Denmark, 1969-1993. *Am J Epidemiol*. 2002;155(12):1088–1095.

51. Yang H, Xia L, Chen J, et al. Stress–glucocorticoid–TSC22D3 axis compromises therapy-induced antitumor immunity. *Nat Med*. 2019;25(9):1428–1441.

52. Zhang Y, Zanos P, Jackson IL, et al. Psychological stress enhances tumor growth and diminishes radiation response in preclinical model of lung cancer. *Radiother Oncol*. 2020;146:126–135.

53. Tyrka AR, Price LH, Marsit C, Walters OC, Carpenter LL. Childhood adversity and epigenetic modulation of the leukocyte glucocorticoid receptor: preliminary findings in healthy adults. *PloS One*. 2012;7(1):e30148.

54. McGowan PO, Sasaki A, D’Alessio AC, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. *Nat Neurosci*. 2009;12(3):342–348.

55. Mu H, Wang N, Zhao L, et al. Methylation of PLCD1 and adenovirus-mediated PLCD1 overexpression elicits a gene therapy effect on human breast cancer. *Exp Cell Res*. 2015;332(2):179–189.

56. Xiang T, Li L, Yin X, et al. Epigenetic silencing of the WNT antagonist Dickkopf3 disrupts normal Wnt/beta-catenin signalling and apoptosis regulation in breast cancer cells. *J Cell Mol Med*. 2013;17(10):1236–1246.

57. Xiao Y, Xiang T, Luo X, et al. Zinc-finger protein 545 inhibits cell proliferation as a tumor suppressor through inducing apoptosis and is disrupted by promoter methylation in breast cancer. *PloS One*. 2014;9(10):e110990.

58. Park C, Rosenblat JD, Brietzke E, et al. Stress, epigenetics and depression: a systematic review. *Neurosci Biobehav Rev*. 2019;102:139–152.